tradingkey.logo
tradingkey.logo
Search

Mass General Brigham Launches Two Trials Using Haystack MRD ctDNA to Guide Post-Surgery Cancer Treatment

ReutersAug 7, 2025 1:21 PM

- Quest Diagnostics Inc DGX.N:

  • MASS GENERAL BRIGHAM LAUNCHES TWO CLINICAL TRIALS TO STUDY HAYSTACK MRD CTDNA AS GUIDE FOR POST-SURGICAL TREATMENT FOR TWO CANCER TYPES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI